Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437341 | 0.97 | OPRM1 (0.61) | OPRM1OPRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL12437596 | 0.96 | HRH3 (0.61) | OPRM1OPRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL12437340 | 0.93 | HRH3 (0.68) | OPRM1OPRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL12437532 | 0.92 | HRH3 (0.69) | OPRM1OPRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL12437525 | 0.92 | HRH3 (0.69) | OPRM1OPRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL12437365 | 0.90 | MEN1 (0.61) | OPRM1OPRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL12437516 | 0.89 | HRH3 (0.60) | OPRM1OPRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL12437577 | 0.88 | OPRM1 (0.63) | OPRM1OPRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL12437576 | 0.88 | MEN1 (0.58) | OPRM1OPRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL14435668 | 0.86 | SLC5A7 (0.50) | OPRM1OPRD1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | OPRM1 2073/4885OPRD1 779/4885MEN1 3974/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | OPRM1 2073/4885OPRD1 779/4885MEN1 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.